Clinical Trial Update: Liposomal Irinotecan Combined with Sintilimab for Second-line Treatment of Progressive Gastric Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial update evaluating liposomal irinotecan with sintilimab as second-line therapy for progressive gastric cancer; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• Liposomal irinotecan (liposomal irinotecan)
• Sintilimab (sintilimab)

Snippet

Sponsor: Ruijin Hospital | Conditions: Gastric Cancer | Phase 2 | Status: NOT_YET_RECRUITING